Retrograde benefit following mitral transcatheter edge-to-edge repair: medium- and long-term results from a single centre
- PMID: 40631498
- DOI: 10.2459/JCM.0000000000001763
Retrograde benefit following mitral transcatheter edge-to-edge repair: medium- and long-term results from a single centre
Abstract
Aims: In patients with significant mitral regurgitation (MR), heart-lung interaction is decisive in defining symptoms and signs of heart failure. Little is known about the direct effects of mitral transcatheter edge-to-edge repair (m-TEER) on pulmonary circulation and changes in lung congestion and function. This study directly evaluates, through the execution of pulmonary function tests, the mid- and long-term impact of m-TEER on lungs.
Methods: Consecutive patients undergoing m-TEER from June 2019 to September 2023 were evaluated at baseline and at 3- and 12-month follow-up. Clinical, laboratory and echocardiographic examinations, quality-of-life questionnaire and walking test were performed, followed by spirometry and diffusing capacity of the lungs for carbon monoxide (DLCO).
Results: Sixty-eight patients (78±6 years, NYHA class III-IV) underwent effective m-TEER. At follow-up they presented improvement in echocardiographic parameters, functional data and quality of life. After TEER, DLCO significantly increased (from 67% ± 17 at baseline to 75% ± 17 and 74% ± 18 at 3- and 12-month respectively, P < 0.001) as well as spirometric indices of forced vital capacity (FVC) (from 84% ± 19 to 96% ± 20 and 91% ± 23, P < 0.001) and forced expiratory volume in the first second (FEV1) (from 90% ± 24 to 99% ± 27 and 97% ± 28, P < 0.001). At 12 months, DLCO was associated with systolic pulmonary artery pressure and right ventricular-to-pulmonary artery coupling, with spirometric measure of FVC with the 6-min walk distance.
Conclusions: This work shows the improvement of spirometric indices and DLCO on patients undergoing m-TEER. These results indicate the retrograde benefit of the procedure resulting in pulmonary decongestion due to the reduction of MR.
Keywords: diffusing capacity of the lungs for carbon monoxide; heart failure; mitral transcatheter edge-to-edge repair; pulmonary congestion; spirometry.
Copyright © 2025 Italian Federation of Cardiology - I.F.C. All rights reserved.
References
-
- Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol 2015; 65:1231–1248.
-
- Borlaug BA, Olson TP. The lungs in heart failure: not an innocent bystander. JACC Heart Fail 2016; 4:450–452.
-
- Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017; 135:e1159–e1195.
-
- Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. ESC/EACTS Scientific Document Group. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2022; 43:561–632.
-
- Kottenberg E, Dumont M, Frey UH, Heine T, Plicht B, Kahlert P, et al. The minimally invasive MitraClip procedure for mitral regurgitation under general anaesthesia: immediate effects on the pulmonary circulation and right ventricular function. Anaesthesia 2014; 69:860–867.